Fundraising Requires More Than a Plan. It Requires Execution. 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

For early-stage life science companies, fundraising and partnering are not one-time activities. They require an ongoing, focused effort to identify the right market, communicate a clear opportunity, build relationships, and follow through consistently.

Many companies have the science, the data, and the ambition to move forward, but do not have a dedicated business development resource to manage that work throughout the year. Leadership teams are often balancing scientific progress, regulatory planning, operations, and fundraising at the same time.

Life Science Nation’s BD Assist program was developed to provide hands-on support for companies that need help executing their fundraising and partnering campaigns.

BD Assist is the execution layer of Life Science Nation’s commercialization system. It builds on the work of understanding a company’s readiness, identifying the right investor and licensing-partner market, and creating a Global Target List that can support a focused campaign.

The result is not simply a list of contacts. It is a structured process for moving from market intelligence to outreach, follow-up, and meeting generation.

From target market to active campaign

Every BD Assist engagement begins with an understanding of the company’s goals, financing needs, technology, milestones, and partnering objectives. Life Science Nation then works with the company to refine its narrative and marketing materials so the opportunity can be communicated clearly to the market.

Using Life Science Nation’s investor and licensing-partner intelligence, the BD Assist team helps construct and prioritize a Global Target List of relevant investors and strategic partners. The target list is informed by company-specific attributes as well as investor behavior, helping companies focus their efforts on the market most relevant to their opportunity.

From there, BD Assist supports campaign strategy, personalized outreach, follow-up, and meeting generation. Outreach activity is tracked through the client’s CRM platform, allowing the company to maintain visibility into campaign progress and investor engagement.

This ongoing execution is a key part of the program. A target list has value only when it becomes a disciplined campaign that continues to build relationships and create opportunities over time.

Extending a company’s business development capacity

BD Assist is designed to become an extension of a company’s business development capability.

Rather than providing recommendations for a company to carry out on its own, Life Science Nation helps manage the campaign workflow. This allows company leadership to stay focused on advancing the science, reaching development milestones, and preparing for productive investor and partner conversations.

The program also includes regular strategy discussions and campaign refinement as the company receives feedback from the market. As priorities evolve, BD Assist can help ensure that outreach remains aligned with the company’s current fundraising or partnering objectives.

For companies participating in RESI, BD Assist can also support their partnering activity and help them make the most of the investor and licensing-partner marketplace.

Part of a broader commercialization process

BD Assist is one part of a connected Life Science Nation commercialization system.

The Assessment Engine helps companies understand their evidence, risks, milestones, capital readiness, and investability. LSN Labs helps companies address gaps and prepare for the market. The Investor and Licensing Partner Database provides market intelligence. The Global Target List helps companies identify and prioritize their target market. BD Assist helps execute the campaign. RESI creates opportunities to meet the global investor and licensing-partner community.

For companies seeking investment, licensing opportunities, or strategic collaborations, this creates a more connected path from preparation to market engagement.

Fundraising is not only about finding names. It is about executing a consistent process that helps the right companies connect with the right market at the right time.

To learn more about BD Assist and discuss whether it is a fit for your company, complete the LSN Labs Company Assessment Report.

Apply for LSN Labs Company Assessment Report

Hot Investor Mandate: Early-Stage Venture Fund Seeks Therapeutics and Other Healthcare Technologies Addressing CNS and Mental Health 

A U.S.-based venture capital firm invests in early-stage neuropsychiatric and mental health opportunities. The firm primarily invests from Pre-Seed through Series A, with initial checks typically ranging from $50K–$1M and capacity for follow-on investment. The firm is comfortable serving as the first institutional investor and can lead or co-invest alongside other investors. Investments may be structured through traditional equity financings or SAFEs. The firm primarily targets U.S.-based companies while remaining open to opportunities globally.  

The firm invests in therapeutics and technologies addressing neuropsychiatric conditions, mental health, and general wellness. Areas of interest include psychedelic medicine, brain-computer interfaces, therapeutic platforms, precision diagnostics, and other technologies addressing neurological and psychiatric conditions. For biotechnology and therapeutics opportunities, the firm generally prefers assets that are at or approaching the IND stage. For medical technology opportunities, the firm is comfortable engaging earlier in the development process.  

From a company and management team perspective, the firm does not impose strict requirements regarding team composition. The firm has a strong preference for founders with prior pharmaceutical or biotechnology industry experience or a demonstrated track record of successful entrepreneurship. The firm may seek a board seat or observer position on a case-by-case basis and takes a flexible approach to governance depending on the company’s stage and financing structure. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based VC Firm Invests in Seed to Growth-Stage Healthcare and Deeptech Companies, With Focus on Healthtech 

The firm is a U.S.-based venture capital investor focused on Seed through growth-stage deep-tech companies, including opportunities across healthcare. The firm invests through direct and special-purpose investment structures and can access matching capital of up to $10M for qualifying companies willing to establish operations in a designated U.S. innovation ecosystem. The firm primarily targets companies with differentiated technologies and evidence of meaningful technical or commercial validation. 

Within healthcare, the firm focuses primarily on healthtech, including digital health and medical technology. For therapeutics, the firm selectively considers companies addressing compelling disease areas through novel technologies and generally requires programs to have completed Phase I development or otherwise achieved substantial technical and clinical de-risking. For digital health opportunities, the firm requires demonstrated customer traction and a minimum level of commercial revenue. Pre-revenue pharmaceutical companies may be considered when meaningful alternative indicators of traction and validation can be demonstrated.  

From a company and management team perspective, the firm seeks companies that can demonstrate clear evidence of technology validation, market traction, or clinical de-risking appropriate to their sector and development stage. The firm takes an active governance approach and requires a board seat as part of its investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Venture Studio and Early-Stage Focused Fund Supports Preclinical Therapeutics Programs With Focus in USA-Based Opportunities

The firm is a U.S.-focused therapeutics venture studio that translates academic discoveries into venture- and pharmaceutical-ready drug development programs. Backed by a specialist life sciences investor and supported by strategic industry partners, the firm combines company creation, scientific development, and very early-stage investment capabilities. The firm works closely with academic institutions to identify promising discoveries, form new biotechnology companies, and advance programs toward milestones suitable for institutional financing. The firm currently focuses primarily on U.S.-based opportunities while expanding its activities into the UK and Israel.  

The firm invests exclusively in traditional therapeutics and targets programs at the earliest stages of development, with clinical-stage assets generally considered too advanced for its model. The firm is broadly modality-agnostic but has a preference for established therapeutic modalities such as small molecules and biologics. Areas of particular interest include oncology, kidney disease, fibrosis, immunology and inflammation, and neuroscience/CNS. The firm remains open to other indications when programs address compelling unmet medical needs and have substantial commercial potential.  

From a company and management team perspective, the firm does not impose strict requirements and is specifically structured to work with academic founders before a conventional management team has been assembled. Academic investigators may serve as scientific founders while the firm’s internal leadership and development team provide interim executive and operational support. The firm works hands-on to advance scientific programs, establish new companies, and prepare them for subsequent institutional financing and continued development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: CVC of Global Pharma Deploys Flexible Early-Stage Capital Across Therapeutics and Healthcare Innovation

A corporate venture capital arm of a global pharmaceutical company is actively identifying next-generation healthcare technologies and emerging growth opportunities. Operating independently from the parent company’s traditional business development activities, the firm takes a primarily financially driven investment approach. The firm focuses on Seed, early-, and mid-stage companies while remaining open to select Pre-Seed opportunities.  

The firm invests globally across Asia, North America, and Europe, with investment sizes tailored to each company’s stage and financing needs. The firm invests across three broad themes: restoration and enhancement of human biological functions, infectious disease eradication, and technologies that strengthen the healthcare value chain. The firm’s mandate extends beyond therapeutics to include enabling technologies, healthcare infrastructure, and platform innovations that could shape future healthcare delivery and development. The firm seeks opportunities both adjacent to and beyond its parent company’s existing businesses, prioritizing breakthrough science, significant unmet medical needs, and technologies with substantial long-term growth potential.  

From a company and management team perspective, the firm seeks scientifically differentiated technologies and founders with the potential to build sustainable healthcare businesses. The firm does not require licensing rights, acquisition options, commercialization agreements, or other strategic rights as a condition of investment. The firm can provide portfolio companies with access to pharmaceutical R&D expertise, development capabilities, industry experience, and a global network. Strategic collaborations, licensing, co-development, or other transactions may be explored separately as portfolio companies mature when mutually beneficial. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

RESI Boston 2026 Innovator’s Pitch Challenge Winners Announced 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the winners of the RESI Boston 2026 Innovator’s Pitch Challenge, held during Biotech Week Boston.

Over the two days o RESI, more than 70 early stage life science companies presented their innovations to an audience of active investors, strategic partners, and industry leaders. Following the final round of pitches, the top three companies were recognized during lunch on day two:

1st Place 2nd Place 3rd Place
Synaptic Bio Orthonika Ironsides Medical
Synaptic Bio Orthonika Ironsides Medical

Congratulations to Synaptic Bio, Orthonika, Ironsides Medical, and every company that took the stage. The caliber of innovation, preparation, and investor engagement throughout the Challenge reflected the exciting work advancing across the global life science ecosystem.

Judges’ Picks Award Winners

In addition to the overall winners, Life Science Nation is proud to recognize the companies that received the highest evaluation scores from the investor judges in each Innovator’s Pitch Challenge session:

These companies stood out to the judging panels for the quality of their presentations and the potential of their technologies to address important unmet needs.

Apply to Pitch at RESI JPM 2027

Applications are now open for the Innovator’s Pitch Challenge at RESI JPM 2027, taking place in San Francisco on January 11 to 12, with virtual partnering January 13 and 18 to 19.

The Innovator’s Pitch Challenge gives early-stage companies the opportunity to present live to active life science investors, receive structured feedback, and build meaningful connections through RESI partnering.

Apply to the Innovator’s Pitch Challenge and secure your opportunity to pitch at RESI JPM.

Apply to Pitch at RESI JPM 2027

Secure Your Dedicated Session and Meeting Space at RESI JPM 2027 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Every January, J.P. Morgan Healthcare Week transforms San Francisco into the global epicenter of life sciences, bringing together top-tier investors, corporate pharma scouts, and biotech innovators. For organizations seeking a visible, accessible base during the busiest week of the year, RESI JPM 2027 offers prime physical space inside the San Francisco Marriott Marquis.

Life Science Nation (LSN) is opening dedicated session and meeting spaces for booking across Monday, January 11 and Tuesday, January 12, 2027. Spaces can be reserved with flexible scheduling options: available by the hour, half-day, or full-day to accommodate presentations, private investor pitches, workshops, or ecosystem receptions. Additionally, hosting organizations receive official RESI JPM Sponsor status, featuring prominent brand exposure across RESI marketing and promotional channels.

Available Spaces and Layouts: Yerba Buena Ballroom (Lower B2 Level)

Located within LSN’s 17,000+ sq. ft. conference footprint across Salons 9–15:

Private Breakout Salons (Salons 10–15):

  • Size and Capacity: ~800 sq. ft. per room, seating up to 70 attendees.
  • Configuration: Fully enclosed private salons ideal for proprietary pitch sessions, closed-door investor roadshows, regional delegation showcases, or a private executive lounge.

Open Session Stage (Salon 9):

  • Size and Capacity: Open ballroom setting accommodating ~60 attendees.
  • Configuration: Positioned directly alongside the high-traffic partnering floor, maximizing foot traffic and casual walk-ins for open panel discussions and cohort spotlights.

Flexible Booking Windows (January 11–12, 2027)

Spaces are available throughout both in-person conference days:

  • Hourly Rentals: For focused company presentations, quick investor roundtables, or press briefings.
  • Half-Day Blocks (Morning / Afternoon): For structured cohort pitch sessions, seminars, or partner workshops.
  • Full-Day / Multi-Day Buyouts: To establish a dedicated branded headquarters and continuous meeting base right inside JPM week.

Immediate Next Steps

Contact LSN: Reach out directly to salescore@lifesciencenation.com to review specific floor plans, pricing tiers, and associated sponsor marketing packages.